Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7439343 | 0.84 | KMT2A (0.63) | KMT2AMEN1LMNAPOLBRECQL | |
| SCHEMBL8569592 | 0.83 | CDK5 (0.53) | CES2CES1KMT2AMEN1RAB9A | |
| SCHEMBL28747256 | 0.83 | CES2 (0.51) | CES2CES1KMT2AMEN1LMNA | |
| SCHEMBL8694860 | 0.82 | KMT2A (0.56) | CES2CES1KMT2AMEN1POLB | |
| SCHEMBL7370589 | 0.82 | ALDH1A1 (0.55) | CES2CES1KMT2AMEN1LMNA | |
| SCHEMBL7369720 | 0.81 | ELANE (0.49) | CES2CES1KMT2AMEN1POLB | |
| SCHEMBL3244377 | 0.81 | CES2 (0.49) | CES2CES1KMT2AMEN1RAB9A | |
| SCHEMBL7364528 | 0.80 | HTT (0.56) | CES2CES1KMT2AMEN1LMNA | |
| SCHEMBL7362471 | 0.78 | PKM (0.49) | CES2CES1KMT2AMEN1POLB | |
| SCHEMBL4960341 | 0.78 | USP2 (0.52) | CES2CES1KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1216244-A1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | Aventis Pharmaceuticals Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019821-A1 | BENZISOXAZOLYL-, PYRIDOISOXAZOLYL- AND BENZTHIENYL-PHENOXY DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-4736037-A | 2-halo-aryl-pyridinemethanols with analgesic or antiinflammatory activity | LACER, S.A. (ES) | 1988-04-05 | — | — | US | disclosed |
| US-4614833-A | 2-halo-pyridines | LACER, S.A. (ES) | 1986-09-30 | — | — | US | disclosed |
| EP-0032516-B1 | NEW 2-HALO-PYRIDINES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | LACER, S.A. (ES) | 1984-05-02 | — | — | EP | disclosed |
| EP-0032516-A1 | New 2-halo-pyridines, their production and pharmaceutical compositions | LACER, S.A. (ES) | 1981-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | DRD4, DRD2, DRD1 | CES2 749/4885CES1 1886/4885KMT2A 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.